These in vitro and in vivo experimental results indicate that NRG1 and PDGFC in the TME significantly promote chemoresistance in BC, suggesting that chemotherapy combined with targeted blockade of the NRG1/PDGFC signaling between CAFs and cancer cells may be an effective strategy for improving BC treatment. This evidence concerns the gene PDGFC and breast cancer.